Trial Profile

Study of an intratumoral delivery of NZ-DTX Depot in men with localized prostate cancer who are scheduled for prostatectomy

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary)
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors LIDDS

Most Recent Events

02 Apr 2025 According to a LIDDS media release, the company's Board of Directors has decided to cease further development of the project areas Nanodotax.
02 Apr 2025 Status changed from planning to discontinued, according to a LIDDS media release.
22 Feb 2024 According to a LIDDS media release, this study was never started due to the cost-cutting measures initiated in June.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com